English   |   Français



 Contact Us 
 















LATEST NEWS:
Craig's Cause spreads hop...
Dec 13, 2016 - On July 29, 2006, Stefanie Condon-Oldreive’s life changed forever. Her father, Craig Schurman Condon, was diagnosed with pancreatic cancer at 63 years old. Eight weeks later...
Read more
NEWSLETTER SIGNUP
YOUR NAME:
EMAIL ADDRESS:
Diagnosing Pancreatic Cancer

Blood Tests
Currently, there is no single blood test that can be used to make a diagnosis of pancreatic cancer.

Initial blood work should include: CBC, Total Bilirubin, LFTs, Creatine, Blood Glucose and INR.

Different tumour markers in the blood are used to detect and monitor many types of cancer. Tumour markers are substances produced by some tumour cells. There are two commercially available tumour marker tests that are of use for patients with pancreatic cancer: cancer antigen 19-9(CA19-9) and carcinoembryonic antigen (CEA). These markers are not accurate enough to be used to screen healthy people for, or to make a diagnosis of, pancreatic cancer. However, CA19-9 and CEA are frequently used to track the progress of treatment in patients with pancreatic cancer.

Imaging Tests
The most important tests used to detect pancreatic cancer are imaging tests such as Ultrasounds, CT scans and MRI scans. These tests use a variety of methods to see inside the body.

Computed Tomography (CT) Scan 
A CT scan, also called a CAT scan, is a sensitive imaging test used to evaluate patients suspected of having pancreatic cancer. It can produce three-dimensional images of the pancreas. It is estimated that this type of CT scan can diagnose about 98% of all pancreatic cancers and distant metastases.

During a CT scan, you will lie on a table that is moved into the machine. The scanner will take detailed and cross-sectional x-ray images from many different angles. This test may take up to 2 hours and can be done on an outpatient basis.

Sometimes a dye, known as a contrast agent, can be injected into a vein or given by mouth in order to produce better CT images of body structures such as the stomach and small intestines. In many centres, basic CT scanners are modified to see the pancreas more accurately. When contrast is used, the individual may feel warm all over the body during the injection. Others may notice a metallic taste in the mouth. The rare individual may develop an allergy with associated with hives and itching.

Magnetic Resonance Imaging (MRI)
MRI uses radio waves and powerful magnets, instead of x-rays as in a CT scan, to view internal structures and organs. The waves are absorbed by the body and then released. A computer translates the patterns formed by this energy release into detailed images of areas inside the body. MRI produces cross-sectional slices like a CT scanner, but also produces slices that are parallel to the length of the body. There is no exposure to radiation with an MRI.

Magnetic Resonance Cholangiopancreatography (MRCP)
Magnetic Resonance Cholangiopancreatography (MRCP) is a type of MRI and is an alternative to ERCP (Endoscopic Retrograde Cholangiopancreatography). It is safer and faster than ERCP, because it is non-invasive and no dye is used. MRCP is used to view the pancreatic and bile ducts, which are difficult to see with CT or MRI.

Ultrasonography
Ultrasonography is another imaging test that is commonly used. These scans are also referred to as ultrasounds, sonograms or ultrasonograms. During this test, sound waves are bounced off internal organs to produce echoes. The computer creates patterns from these echoes. Since normal and abnormal tissue produce different patterns, pancreatic cancer can be detected.

Unlike x-rays an ultrasound does not use radiation; therefore, it is considered a safe alternative for imaging pregnant women.

Positron Emission Tomography (PET scanner)
Positron Emission Tomography, or PET scan, is an imaging test that shows anatomy and biological function. During a PET scan, a small amount of radioactive glucose (sugar) is injected into a vein. Then a special camera detects the radioactivity that is taken up by cancer tissue.

PET scans are increasingly read alongside CT or (MRI) scans, the combination ("co-registration") giving both anatomic and metabolic information (i.e., what the structure is, and what it is doing biochemically).  

Endoscopic Retrograde Cholangiopancreatography (ERCP)
Endoscopic Retrograde Cholangiopancreatography, or ERCP, is an invasive procedure that is used, with a dye, to view the bile and pancreatic ducts for any blockages. During an ERCP, you receive an anaesthetic to numb your throat and medication to make you sleepy. A thin tube is passed down your throat, through your stomach, and into your small intestine. 

ERCP is especially helpful for patients with jaundice because a stent can be inserted and left in place to keep ducts open, often relieving the jaundice and its associated symptoms. In addition, during the ERCP doctors can collect small particles of any tumours there may be, to be analyzed under a microscope.

Biopsy
Since the only definitive way to diagnose cancer is to directly visualize cancer cells under a microscope, a biopsy should be performed when pancreatic cancer is suspected. A biopsy is the process of removing tissue samples, which are then examined under a microscope to check for cancer cells. Fine-needle aspiration (FNA) is a technique in which cells are aspirated from a tumour using a needle and syringe with the application of negative pressure. The technique can be performed using image-directed guidance (Endoscopic Ultrasound-guided, CT guided) and is particularly helpful in the diagnosis of relatively inaccessible tumours. 

Cancer is then diagnosed if there is evidence of distinct, abnormal growth of cells. 
 

There is some controversy regarding the use of biopsy tissue diagnosis of pancreatic cancer before performing surgery on a suspected tumour. Some centres advocate the practice of operating on all patients thought to have early pancreatic cancer and argue against a preoperative biopsy tissue diagnosis. The concern is that false negative biopsy results can occur due a sampling error which could influence the decision to proceed with surgical removal of the tumour. 

Some surgeons are hesitant to perform an operation on patients without a positive tissue diagnosis to confirm pancreatic cancer. Tissue diagnosis is almost always required prior to initiation of chemotherapy, radiation therapy or the use of permanent metallic stents for relief in obstructive jaundice.

It is also possible that biopsy of the pancreas might spread cancer cells into the abdomen. Studies of the risk of spreading cancer with CT-guided biopsy have suggested that this risk is actually very low.


 Send your information to info@craigscause.ca to Ask a Doctor what tests are right for you.

SHARE THIS PAGE
 
Craig's Cause Pancreatic Cancer Society Address:
P.O. Box 8561
Halifax, N.S. B3K 5M3
Toll Free: 1.877.212.9582
Charitable Business No: 84235 2759 RR0001

Copyright 2014, Craig's Cause. All rights reserved.
Website Design by Amplify Media